IMT 001
Alternative Names: IMT-001 - TrueBinding; IMT001Latest Information Update: 28 Dec 2024
At a glance
- Originator TrueBinding
- Class Antineoplastics; Hepatoprotectants; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Galectin 3 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA (Parenteral)
- 28 Aug 2024 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 13 Nov 2020 Preclinical trials in Non-alcoholic steatohepatitis in USA (Parenteral) before November 2020